Bajaj Finserv
|

Bajaj Finance Limited

|
Sign In
EMI Card
Notifications
Notifications
Cart
Prime
Partners
  • Fixed Deposit (IFA) Partner Fixed Deposit (IFA) Partner
  • Loan (DSA) Partner Loan (DSA) Partner
  • Debt Management Partner Debt Management Partner
  • EMI Network Partner EMI Network Partner
  • Become a Merchant Become a Merchant
  • Demat and mutual fund partner Demat and mutual fund partner
  • Partners Sign In Partners Sign In
Menu
  • Loans
    • All Loans
    • Personal Loan Apply Online Check Offer
      • Overview Flexi Personal Loan Features and Benefits Eligibility Calculator Fees and Charges How to Apply FAQs Manage your Loans Manage your Flexi Loans Contact Us
      • Loans for your Goals

        • Loan for Wedding
        • Loan for Higher Education
        • Loan for Home Renovation
        • Loan for Medical Emergency
    • Insta Personal Loan Check Offer Pre-approved Offer
      • Overview Features Eligibility Calculator Fees and Charges How to Apply Manage your Loans
      • Loans for your Goals

        • Loan for Wedding
        • Loan for Higher Education
        • Loan for Home Renovation
        • Loan for Medical Expenses
    • Business Loan Apply Online Check Offer

        Unsecured

      • MSME World Overview Features EMI Calculator Eligibility How to Apply Fees & Charges Manage your Loans Manage your Flexi Loans
      • Secured

      • Overview Features EMI Calculator Eligibility How to Apply Fees & Charges Manage your Loans Manage your Flexi Loans
      • Types of Business Loans

      • Business Loan for Chartered Accountants Loan Against Property for Chartered Accountant Personal Loan for Chartered Accountants
    • Gold Loan Apply Online

        New Loan

      • Overview Features EMI Calculator Eligibility How to Apply Manage your Gold Loan Interest Rate and Charges Gold Rate
      • Balance Transfer

      • Overview Features EMI Calculator Eligibility How to Apply Interest Rate and Charges
    • Loans for Doctors Apply Online Check Offer

        UNSECURED

      • Doctor World Overview Features Eligibility How to Apply Fees & Charges Manage your Loans Manage your Flexi Loans
      • SECURED

      • Overview EMI Calculator Features Eligibility How to Apply Fees and charges Manage your loan
      • Types of Doctor Loans

      • Business Loan for Doctors Personal Loan For Doctors Loan Against Property for Doctors Indemnity Insurance Medical Practice Loan
    • Medical Equipment Finance Apply Online
      • Overview Features Eligibility How to Apply Fees & Charges
    • Loans for CAs Apply Online Check Offer

        UNSECURED

      • Overview Features Eligibility How to Apply Fees & Charges Manage your Loans Manage your Flexi Loans
      • SECURED

      • Overview EMI Calculator Features Eligibility How to Apply Fees and charges Manage your loan
      • Types of CA Loans

      • Business Loan for Chartered Accountants Loan Against Property for Chartered Accountants Personal Loan for Chartered Accountants
    • Commercial Lending
      • Overview Term Loans Working Capital Products Corporate Lease Rental Discounting
    • Home Loan Apply Online Check Offer

        Home Loan

      • Home Loan World Overview Features EMI Calculator Eligibility How to Apply Fees and Charges Home Loan Interest Rate
      • Balance Transfer

      • Overview Features Eligibility How to Apply Fees and Charges
      • Categories

      • Home Loan for Doctors Home Loan for Self-employed Home Loan for Salaried
      • Categories

      • Home Loan Balance Transfer for Doctors Home Loan Balance Transfer for Self-employed Home Loan Balance Transfer for Salaried
    • Loan Against Property Apply Online

        LOAN AGAINST PROPERTY

      • Overview Features EMI Calculator Eligibility How to Apply Fees & Charges Loan Against Property Interest Rate
      • BALANCE TRANSFER

      • Overview Features Eligibility How to Apply Fees & Charges
    • Lease Rental Discounting
    • Loan Against Securities Apply Online

        LOAN AGAINST SHARES

      • Overview Features Eligibility How to Apply Fees & Charges Manage your Loan Against Securities FAQ
      • Loan Against Mutual Funds

      • Overview Features Eligibility How to Apply Fees & Charges FAQ
      • Loan Against Bonds

      • Overview Features and Benefits Eligibility How to Apply Fees and Charges FAQs
      • Loan Against Insurance Policy

      • Overview Features and Benefits Eligibility How to Apply Fees and Charges FAQs
      • ESOP Financing

      • Overview Features and Benefits Eligibility How to Apply Fees and Charges FAQs
    • Two-wheeler Loan Apply Online Check Offer
      • Overview Eligibility Features Interest Rates How to Apply Manage your Two-wheeler Loan FAQs
    • New Car Finance Apply Now Check Offer
      • Auto World Overview Features Eligibility How to Apply Interest Rates and Charges FAQs Manage your loan Manage your flexi loan
    • Used Car Loan Apply Now Check Offer

        Used Car Finance

      • Auto World Explore Used Cars and Loan Overview Features and benefits Eligibility EMI Calculator Used Car Loan Eligibility Calculator Fees and charges How to Apply FAQs Manage your loan Manage your flexi loan
      • Categories

      • Loan against car Car loan balance transfer
    • Loan Against Car Apply Now Check Offer

        Loan Against Car

      • Auto World Overview Features and benefits Eligibility EMI Calculator Loan Against Car Eligibility Calculator Fees and charges How to Apply FAQS Manage your loan Manage your flexi loan
      • Categories

      • Used car loan Car loan balance transfer
    • Car Loan Balance Transfer and Top-up Apply Now Check Offer

        Balance Transfer

      • Auto World Overview Features and benefits Eligibility EMI Calculator Car Loan Balance Transfer and Top Up Eligibility Calculator Fees and Charges How to Apply Manage your loan FAQS Manage your flexi loan
      • Categories

      • Used car loan Loan against car
    • Microfinance Group Loan
    • Tractor Loan
    • Loan for Lawyer
    • Easy EMI Loan
  • All on EMI
    • Electronics
    • Two-wheelers
    • Lifestyle
    • Travel
      • Our Partner Make My Trip Goibibo IRCTC
    • Shop on Ecommerce
      • Our Partner Flipkart Amazon
    • Offers & Promotions
    • Tractor
  • Bajaj Mall
    • Smartphones
    • Washing Machines
    • LED TVs
    • Refrigerators
    • Air Conditioners
    • Water Purifiers
    • Two-wheelers
    • Smartwatches
    • Laptops
    • Mattresses
    • Furniture
    • Kitchen Appliances
    • Cycles
    • Fitness Equipment
    • Air Cooler
    • Watches
    • Audio Devices
    • Camera Accessories
  • Card
    • Insta EMI Card Apply Online
      • Overview Features and Benefits Eligibility Fees and Charges How to Apply Manage your Insta EMI Card Contact Us
  • Investments
    • All Investments
    • Fixed Deposit Open FD
      • Overview FD Calculator Features and Benefits FD Interest Rates Eligibility and Documents How to Invest FAQs Manage your FD Contact Us
      • FIXED DEPOSIT FOR YOUR GOALS

        • Fixed Deposit for Retirement Fund
        • Fixed Deposit for Higher Education
        • Fixed Deposit for Home Expenses
        • Fixed Deposit for Wedding Expenses
    • Mutual Funds Open MF Account Explore Funds

        About the Product

      • SIP Calculator Overview Explore All MFs How to Invest FAQs Contact Us
      • Fund Category

      • Debt Funds Equity Funds Hybrid Funds ELSS Funds Thematic Funds Multi Cap Fund NFO Large Cap Mutual Funds Mid Cap Mutual Funds Small Cap Mutual Funds Liquid Mutual Funds Aggressive Hybrid Mutual Funds
      • Funds by Returns

      • 1 Month Returns 3 Months Returns 1 Year Returns 3 Years Returns Max Returns
      • Quick Links

      • Portfolio Order in progress Open mutual fund account Dashboard New Fund Offer (NFO)
    • Stock Trading Open A/C
      • Start Trading Open Demat Account Overview FAQ Contact Us
    • Partner Portal
    • Become Our Partner
  • Insurance
    • Insurance Mall
    • Health Insurance Explore Plans

        Health Insurance

      • Overview Get Quote FAQs
      • Family Health Insurance

      • Aditya Birla Group Activ Health Plan (ABCD) Bajaj Allianz Health Guard Insurance Plan ManipalCigna Pro-Health Group Niva Bupa Health Plus Plan Aditya Birla Active Assure Diamond
      • Top-up Health Insurance

      • Group Activ Health Super Top-Up Bajaj Allianz Extra care plus plan
      • Partners

      • Aditya Birla Health Insurance Bajaj Allianz General Insurance Niva Bupa Health Insurance Bajaj Finserv Health ManipalCigna Health Insurance
    • Car Insurance Explore Plans

        Car Insurance

      • Overview Get Quote FAQs
      • Partners

      • ACKO General Insurance Bajaj Allianz General Insurance SBI General Insurance
      • Comprehensive Car Insurance

      • ACKO Car Insurance Bajaj Allianz Car Insurance SBI General Car Insurance
      • Own Damage

      • Bajaj Allianz Car Insurance SBI General Car Insurance
    • Pocket Insurance Explore Plans

        Best Seller

      • Personal Accident Cover Group Activ Health Super top up Cover
      • Under 699

      • Cancer Secure Gym Injury Insurance Pregnancy Complications Cover Baggage Insurance
      • Health Must Have

      • Niva Bupa Health Plus Dental Cover Sports/Fitness Injury Fracture Cover Health Plus Hospital Cash
      • Monsoon Insurance

      • Dengue & Malaria Cover Monsoon Insurance Viral Fever(Infection) CPP Liv Protect Group Activ Secure Policy- Personal Accident Cover 18-55 Years
    • Investment Plans Explore Plans

        Investment Plans

      • Overview
      • Partners

      • HDFC Life Bajaj Allianz Life Insurance
      • Guaranteed Savings

      • HDFC Life Guaranteed Savings Plan Bajaj Allianz Life POS Goal Suraksha Plan
    • Life Insurance Explore Plans

        Life Insurance

      • Overview Get Quote
      • Partner

      • Bajaj Allianz Life Insurance HDFC Life insurance Future Generali India Life Insurance
    • Professional Indemnity Explore Now

        Professional Indemnity

      • Overview Get Quote Bajaj Allianz Professional Indemnity Insurance Plan View All
      • Partners

      • Bajaj Allianz General Insurance
    • Manage your Insurance
  • Payments
    • All Payments
    • Mobile Recharge Pay Now
      • Jio Airtel Vi BSNL
    • Electricity Bill Payment Pay Now
      • Maharashtra State Electricity Distbn Co Ltd West Bengal Electricity Torrent Power Tamil Nadu Electricity Board (TNEB) Central Power Distribution Corporation Ltd. of Andhra Pradesh (APCPDCL) Calcutta Electric Supply Corporation (CESC) Jaipur Vidyut Vitran Nigam (JVVNL) APEPDCL-Eastern Power Distribution CO AP Ltd South Bihar Power Distribution Company Ltd. Southern Power Distribution Co Ltd of Andhra Pradesh Purvanchal Vidyut Vitaran Nigam Limited
    • Gas Booking Pay Now
      • Indane Gas (Indian Oil) Bharat Gas (BPCL) HP Gas (HPCL)
    • Loan Repayment Pay Now
      • Bajaj Finance Limited Agent Collection DMI Finance Private Limited Annapurna Finance Private Limited-MFI Bajaj Auto Finance Ujjivan Small Finance Bank TVS Credit IIFL Finance Limited
    • FASTag Buy New Recharge
      • IDFC FIRST Bank - FASTag Airtel Payments Bank NETC FASTag ICICI Bank FASTag HDFC  Bank - FASTag State Bank of India - NETC FASTag Kotak Mahindra Bank - FASTag Axis Bank FASTag IndusInd Bank FASTag
    • DTH Pay Now
      • Dish TV Videocon D2H Airtel DTH Tata Sky Sun Direct TV
    • Credit Card Bill payment Pay Now
      • SBI Card RBL Bank Credit Card HDFC Bank Credit Card ICICI Bank Credit Card Axis Bank Credit Card DBS Credit Card BoB Credit Card IDFC FIRST Bank Credit Card Yes Bank Credit Card Kotak Mahindra Bank Credit Card AU Bank Credit Card
    • Bajaj Pay Wallet
    • Bajaj Pay Gift Card Buy Now
      • My Cards Gift Card Categories
    • Rewards
      • Rewards & Offers Flipkart Gift Card Redbus Gift Card Swiggy Gift Card Amazon Gift Card Zomato Gift Card
  • Offers
    • All Offers
    • Loans
    • Electronics and Appliances
    • Personal Loan
    • EMI Card
    • Investment
    • Business Loan
    • Lifestyle
    • Home Loan
    • Insurance
    • Doctor Loan
    • Two wheeler
    • CA Loan
    • Used Cars
    • Loan Against Securities
    • Broking
    • Rewards
    • Gold Loan
    • Payments
  • Services
    • Locate Us
      • Branches EMI Network Partner Stores Hospitals & Wellness Centres Insurance Network Hospitals Collection Centres
    • All Service Guides
    • Raise a Request
      • Overview Raise a Request Follow-up on an open request Re-open a closed request
    • Manage your Profile
      • Overview Contact Details Personal Details GST Details
    • Manage your Mandate
      • Overview Register Mandate Change Mandate
    • Repay your Loans
      • Overview Clear Overdue EMIs Pay Advance EMIs Part-prepay your Loans Foreclose your Loans Manage your loan settlement
    • Manage your Loans
      • Overview Consumer Durable Loans Flexi Loans Loan Against Fixed Deposit Loan Against Securities Gold Loan Two-wheeler Loan
    • Manage your Cards
      • Insta EMI card Health EMI Network Card
    • Manage your Investments
      • Fixed Deposit Systematic Deposit Plan
    • Manage your Insurance
      • Overview Policy Details Renew your Policy Claim your Policy Cancel your Policy Surrender your Policy
  • About Bajaj Finserv
    • Investor Relations
    • People and Committees
    • About Us
    • Impact
    • TICC
    • Careers
  • pay emi image Pay EMI
  • Do not call image Do not call
  • Download the app image Download the app
Sign In

Main Menu

  • Food & Grocery
    Main Menu
    Food & Grocery
    • Food & Beverages
    • Grocery
    • Fashion
    • Beauty & Personal Care
    • Health & Wellness
    • Home & Kitchen
  • Bajaj Pay
    Main Menu
    Bajaj Pay
    • Bajaj Pay
    • Wallet
    • Refer & Earn
    • Mobile Recharge
    • Buy FASTag
    • Bill Payments & Other Recharges
    • Add Money
  • Loans
    Main Menu
    Loans
    • Personal Loan
    • Gold Loan
    • Business Loan
    • Loan for Doctors
    • Home Loan
    • Secured Business Loan
    • Loan Against Property
    • Loan Against Shares
    • Loan for Chartered Accountants
    • Medical Equipment Finance
    • Loan Against Property Balance Transfer
    • Home Loan Balance Transfer
    • Loan Against Mutual Funds
    • Loan Against Bonds
    • Loan Against Insurance Policy
    • ESOP Financing
    • Two-wheeler Loan
    • Buy a Used Car
    • Tractor Loan
    • Used Car Loan
    • Loan Against Car
    • Car Loan Balance Transfer and Top-up
    • New Car Loan
    • Loan for Lawyer
    • Industrial Equipment Finance
    • Industrial Equipment Balance Transfer
    • Industrial Equipment Refinance
    • Easy EMI Loan
  • Electronics & Smartphones
    Main Menu
    Electronics & Smartphones
    • Smartphones
    • Air Conditioner
    • Led TVs
    • Air Coolers
    • Refrigerators
    • Washing Machines
    • Laptops
    • Easy EMI Loan
  • EMI Card
    Main Menu
    EMI Card
    • Insta EMI Card
  • Share Market
    Main Menu
    Share Market
    • Trading Account
    • Open Demat Account
    • Margin Trading Financing
    • Share Market
    • Invest in IPO
    • All stocks
    • Top gainers
    • Top losers
    • 52 week high
    • 52 week low
    • Loan against shares
  • MSME World
    Main Menu
    MSME World
    • Business Loan
    • Secured Business Loan
    • Loan against property
    • Loans against property balance transfer
    • Loan against shares
    • Home Loan
    • Loans against mutual funds
    • Loan against bonds
    • Loan against insurance policy
    • Industrial Equipment Finance
    • Industrial Equipment Balance Transfer
    • Industrial Equipment Refinance
  • Insurance
    Main Menu
    Insurance
    • Health Insurance
    • Term Life Insurance
    • ULIP Plan
    • Savings Plan
    • Retirement Plans
    • Child Plans
    • Investment Plans
    • Wallet Care
    • Waller Care Entertainment +
    • Personal Accident Care
    • EMI/SIP Cover
    • Health Prime Max
    • Fonesafe Lite
    • Mobile Protect
    • Wallet Protekt
    • Dengue Cover
    • Niva Bupa Health Plus
    • Health Plus Hospital Cash
    • Four Wheeler Insurance
  • Bajaj Prime
    Main Menu
    Bajaj Prime
    • Get Bajaj Prime
  • Investments
    Main Menu
    Investments
    • Fixed Deposit
    • Renew Fixed Deposit
    • ULIP Plan
    • Savings Plan
    • Retirement Plans
    • Child Plans
    • Free Demat Account
    • Invest in Stocks
    • Invest in IPO
    • Margin Trading Facility
    • Equity Mutual Funds
    • Debt Mutual Funds
    • Hybrid Mutual Funds
    • New Fund Offers
    • Open Mutual Fund Account
  • Gold Loan
    Main Menu
    Gold Loan
    • Apply for Gold Loan
    • Transfer your Gold Loan with Us
  • Two Wheeler World
    Main Menu
    Two Wheeler World
    • Bike
    • Scooter
    • Electric Vehicle
    • Best Sellers
    • Popular Brands
  • Credit Score
    Main Menu
    Credit Score
    • Check your Credit Score
  • Fun Zone
    Main Menu
    Fun Zone
    • Engagement Zone
    • Game Zone
  • Auto World
    Main Menu
    Auto World
    • New Car Loan
    • Used Car Loan
    • Loan Against Car
    • Car Loan Balance Transfer and Top-up
    • Buy a Used Car
  • Easy EMI Loan
    Main Menu
    Easy EMI Loan
    • Mobiles and Electronics on Easy EMI
  • Calculators
    Main Menu
    Calculators
    • Personal Loan EMI Calculator
    • Personal Loan Eligibility Calculator
    • Home Loan EMI Calculator
    • Home Loan Eligibility Calculator
    • Good & Service Tax (GST) Calculator
    • Flexi Day Wise Interest Calculator
    • Flexi Transaction Calculator
    • Secured Business Loan Eligibility Calculator
    • Fixed Deposits Interest Calculator
    • Two wheeler Loan EMI Calculator
    • New Car Loan EMI Calculator
    • Used Car Loan EMI Calculator
    • All Calculator
  • Lifestyle
    Main Menu
    Lifestyle
    • Hot Deals
    • Clearance Sale
    • Kitchen Appliances
    • Tyres
    • Camera & Accessories
    • Mattresses
    • Furniture
    • Watches
    • Music & Audio
    • Cycles
    • Mixer & Grinder
    • Luggage & Travel
    • Fitness Equipment
    • Fans
  • Doctor World
    Main Menu
    Doctor World
    • Personal Loan for Doctors
    • Business loan for Doctors
    • Medical Equipment Finance
    • Secured Business Loan
    • Loan against property
    • Loan against share
    • Gold Loan
    • Home Loan
  • All on EMI
    Main Menu
    All on EMI
    • Smartphones
    • Air Conditioners
    • LED TVs
    • Air Coolers
    • Refrigerators
    • Washing Machines
    • Laptops
    • Water Purifiers
    • Tablets
    • Kitchen Appliances
    • Mattresses
    • Furniture
    • Music and Audio
    • Cameras & Accessories
    • Cycle
    • Watches
    • Tyres
    • Luggage & Travel
    • Fitness Equipment
    • Tractor
    • Easy EMI Loan
  • Home Loan World
    Main Menu
    Home Loan World
    • Home Loan
    • Transfer your existing Home loan
    • Loan against Property
    • Home Loan for Salaried
    • Home loan for self employed
    • Home Loan EMI Calculator
    • Home Loan eligibility calculator
    • Home Loan balance transfer
  • Deals and Savings
    Main Menu
    Deals and Savings
    • Easy EMI
    • Offer World
    • 1 EMI OFF
    • New Launches
    • Zero Down Payment
    • Clearance Sale
    • Bajaj Mall Sale
  • Articles
    Main Menu
    Articles
    • Articles
  • Loan Payments
    Main Menu
    Loan Payments
    • Overdue Payments
    • Other Payments
  • Bank details/ Documents
    Main Menu
    Bank details/ Documents
    • Document Center
    • Bank details & Documents
    • Tax Invoice Certificate
  • Do Not Call Service
    Main Menu
    Do Not Call Service
    • Do Not Call Service
  • Your Things
    Main Menu
    Your Things
    • Your Orders
    • Hamara Mall Orders
  • Rewards
    Main Menu
    Rewards
    • Explore Bajaj Prime
    • Explore Rewards
    • Buy Deals & Gift cards
  • Partners
    Main Menu
    Partners
    • Fixed Deposit (IFA) Partner
    • Loan (DSA) Partner
    • Debt Management Partner
    • EMI Network Partner
    • Become a Merchant
    • Partner Sign-in
  • What's New
    Main Menu
    What's New
    • Food & Shopping
    • Credit Card Hub
    • ULIP Plans
    • Top Gainers Stock
    • Top Losers Stock
    • Saving Plan
    • Term Insurance
    • Easy EMI Loan
  • Watch Live
    Main Menu
    Watch Live
    • Live Videos
  • Help and Support
  • Settings
    Main Menu
    Settings
    • Update Profile
    • Manage Consent
    • Refer and Earn
    • About Us
    • Important Information
    • Terms of Service
    • Privacy Policy
    • Fair Practice Code
    • Citizen Charter
    • LogOut
    • TICC
  • Home
  • Account
  • More
  • Pay EMIs
  • Menu
Menu
Food & Grocery

Food & Grocery

  • Food & BeveragesFood & Beverages
  • GroceryGrocery
  • FashionFashion
  • Beauty & Personal CareBeauty & Personal Care
  • Health & WellnessHealth & Wellness
  • Home & KitchenHome & Kitchen
Bajaj Pay

Bajaj Pay

  • Bajaj PayBajaj Pay
  • WalletWallet
  • Refer & EarnRefer & Earn
  • Mobile RechargeMobile Recharge
  • Buy FASTagBuy FASTag
  • Bill Payments & Other RechargesBill Payments & Other Recharges
  • Add MoneyAdd Money
Loans

Loans

  • Personal LoanPersonal Loan
  • Gold LoanGold Loan
  • Business LoanBusiness Loan
  • Loan for DoctorsLoan for Doctors
  • Home LoanHome Loan
  • Secured Business LoanSecured Business Loan
  • Loan Against PropertyLoan Against Property
  • Loan Against SharesLoan Against Shares
  • Loan for Chartered AccountantsLoan for Chartered Accountants
  • Medical Equipment FinanceMedical Equipment Finance
  • Loan Against Property Balance TransferLoan Against Property Balance Transfer
  • Home Loan Balance TransferHome Loan Balance Transfer
  • Loan Against Mutual FundsLoan Against Mutual Funds
  • Loan Against BondsLoan Against Bonds
  • Loan Against Insurance PolicyLoan Against Insurance Policy
  • ESOP FinancingESOP Financing
  • Two-wheeler LoanTwo-wheeler Loan
  • Buy a Used CarBuy a Used Car
  • Tractor LoanTractor Loan
  • Used Car LoanUsed Car Loan
  • Loan Against CarLoan Against Car
  • Car Loan Balance Transfer and Top-upCar Loan Balance Transfer and Top-up
  • New Car LoanNew Car Loan
  • Loan for LawyerLoan for Lawyer
  • Industrial Equipment FinanceIndustrial Equipment Finance
  • Industrial Equipment Balance TransferIndustrial Equipment Balance Transfer
  • Industrial Equipment RefinanceIndustrial Equipment Refinance
  • Easy EMI LoanEasy EMI Loan
Electronics & Smartphones

Electronics & Smartphones

  • SmartphonesSmartphones
  • Air ConditionerAir Conditioner
  • Led TVsLed TVs
  • Air CoolersAir Coolers
  • RefrigeratorsRefrigerators
  • Washing MachinesWashing Machines
  • LaptopsLaptops
  • Easy EMI LoanEasy EMI Loan
EMI Card

EMI Card

  • Insta EMI CardInsta EMI Card
Share Market

Share Market

  • Trading AccountTrading Account
  • Open Demat AccountOpen Demat Account
  • Margin Trading FinancingMargin Trading Financing
  • Share MarketShare Market
  • Invest in IPOInvest in IPO
  • All stocksAll stocks
  • Top gainersTop gainers
  • Top losersTop losers
  • 52 week high52 week high
  • 52 week low52 week low
  • Loan against sharesLoan against shares
msme-world

MSME World

  • Business LoanBusiness Loan
  • Secured Business LoanSecured Business Loan
  • Loan against propertyLoan against property
  • Loans against property balance transferLoans against property balance transfer
  • Loan against sharesLoan against shares
  • Home LoanHome Loan
  • Loans against mutual fundsLoans against mutual funds
  • Loan against bondsLoan against bonds
  • Loan against insurance policyLoan against insurance policy
  • Industrial Equipment FinanceIndustrial Equipment Finance
  • Industrial Equipment Balance TransferIndustrial Equipment Balance Transfer
  • Industrial Equipment RefinanceIndustrial Equipment Refinance
Insurance

Insurance

  • Health InsuranceHealth Insurance
  • Term Life InsuranceTerm Life Insurance
  • ULIP PlanULIP Plan
  • Savings PlanSavings Plan
  • Retirement PlansRetirement Plans
  • Child PlansChild Plans
  • Investment PlansInvestment Plans
  • Wallet CareWallet Care
  • Waller Care Entertainment +Waller Care Entertainment +
  • Personal Accident CarePersonal Accident Care
  • EMI/SIP CoverEMI/SIP Cover
  • Health Prime MaxHealth Prime Max
  • Fonesafe LiteFonesafe Lite
  • Mobile ProtectMobile Protect
  • Wallet ProtektWallet Protekt
  • Dengue CoverDengue Cover
  • Niva Bupa Health PlusNiva Bupa Health Plus
  • Health Plus Hospital CashHealth Plus Hospital Cash
  • Four Wheeler InsuranceFour Wheeler Insurance
Bajaj Prime

Bajaj Prime

  • Get Bajaj PrimeGet Bajaj Prime
Investments

Investments

  • Fixed DepositFixed Deposit
  • Renew Fixed DepositRenew Fixed Deposit
  • ULIP PlanULIP Plan
  • Savings PlanSavings Plan
  • Retirement PlansRetirement Plans
  • Child PlansChild Plans
  • Free Demat AccountFree Demat Account
  • Invest in StocksInvest in Stocks
  • Invest in IPOInvest in IPO
  • Margin Trading FacilityMargin Trading Facility
  • Equity Mutual FundsEquity Mutual Funds
  • Debt Mutual FundsDebt Mutual Funds
  • Hybrid Mutual FundsHybrid Mutual Funds
  • New Fund OffersNew Fund Offers
  • Open Mutual Fund AccountOpen Mutual Fund Account
Gold Loan

Gold Loan

  • Apply for Gold LoanApply for Gold Loan
  • Transfer your Gold Loan with UsTransfer your Gold Loan with Us
Two Wheeler World

Two Wheeler World

  • BikeBike
  • ScooterScooter
  • Electric VehicleElectric Vehicle
  • Best SellersBest Sellers
  • Popular BrandsPopular Brands
Credit Score

Credit Score

  • Check your Credit ScoreCheck your Credit Score
Fun Zone

Fun Zone

  • Engagement ZoneEngagement Zone
  • Game ZoneGame Zone
Auto World

Auto World

  • New Car LoanNew Car Loan
  • Used Car LoanUsed Car Loan
  • Loan Against CarLoan Against Car
  • Car Loan Balance Transfer and Top-upCar Loan Balance Transfer and Top-up
  • Buy a Used CarBuy a Used Car
Easy EMI Loan

Easy EMI Loan

  • Mobiles and Electronics on Easy EMIMobiles and Electronics on Easy EMI
Calculators

Calculators

  • Personal Loan EMI CalculatorPersonal Loan EMI Calculator
  • Personal Loan Eligibility CalculatorPersonal Loan Eligibility Calculator
  • Home Loan EMI CalculatorHome Loan EMI Calculator
  • Home Loan Eligibility CalculatorHome Loan Eligibility Calculator
  • Good & Service Tax (GST) CalculatorGood & Service Tax (GST) Calculator
  • Flexi Day Wise Interest CalculatorFlexi Day Wise Interest Calculator
  • Flexi Transaction CalculatorFlexi Transaction Calculator
  • Secured Business Loan Eligibility CalculatorSecured Business Loan Eligibility Calculator
  • Fixed Deposits Interest CalculatorFixed Deposits Interest Calculator
  • Two wheeler Loan EMI CalculatorTwo wheeler Loan EMI Calculator
  • New Car Loan EMI CalculatorNew Car Loan EMI Calculator
  • Used Car Loan EMI CalculatorUsed Car Loan EMI Calculator
  • All CalculatorAll Calculator
Lifestyle

Lifestyle

  • Hot DealsHot Deals
  • Clearance SaleClearance Sale
  • Kitchen AppliancesKitchen Appliances
  • TyresTyres
  • Camera & AccessoriesCamera & Accessories
  • MattressesMattresses
  • FurnitureFurniture
  • WatchesWatches
  • Music & AudioMusic & Audio
  • CyclesCycles
  • Mixer & GrinderMixer & Grinder
  • Luggage & TravelLuggage & Travel
  • Fitness EquipmentFitness Equipment
  • FansFans
Doctor World

Doctor World

  • Personal Loan for DoctorsPersonal Loan for Doctors
  • Business loan for DoctorsBusiness loan for Doctors
  • Medical Equipment FinanceMedical Equipment Finance
  • Secured Business LoanSecured Business Loan
  • Loan against propertyLoan against property
  • Loan against shareLoan against share
  • Gold LoanGold Loan
  • Home LoanHome Loan
All on EMI

All on EMI

  • SmartphonesSmartphones
  • Air ConditionersAir Conditioners
  • LED TVsLED TVs
  • Air CoolersAir Coolers
  • RefrigeratorsRefrigerators
  • Washing MachinesWashing Machines
  • LaptopsLaptops
  • Water PurifiersWater Purifiers
  • TabletsTablets
  • Kitchen AppliancesKitchen Appliances
  • MattressesMattresses
  • FurnitureFurniture
  • Music and AudioMusic and Audio
  • Cameras & AccessoriesCameras & Accessories
  • CycleCycle
  • WatchesWatches
  • TyresTyres
  • Luggage & TravelLuggage & Travel
  • Fitness EquipmentFitness Equipment
  • TractorTractor
  • Easy EMI LoanEasy EMI Loan
Home Loan World

Home Loan World

  • Home LoanHome Loan
  • Transfer your existing Home loanTransfer your existing Home loan
  • Loan against PropertyLoan against Property
  • Home Loan for SalariedHome Loan for Salaried
  • Home loan for self employedHome loan for self employed
  • Home Loan EMI CalculatorHome Loan EMI Calculator
  • Home Loan eligibility calculatorHome Loan eligibility calculator
  • Home Loan balance transferHome Loan balance transfer
Deals and Savings

Deals and Savings

  •  Easy EMI Easy EMI
  • Offer WorldOffer World
  • 1 EMI OFF1 EMI OFF
  • New LaunchesNew Launches
  • Zero Down PaymentZero Down Payment
  • Clearance SaleClearance Sale
  • Bajaj Mall SaleBajaj Mall Sale
Articles

Articles

  • ArticlesArticles
Loan Payments

Loan Payments

  • Overdue PaymentsOverdue Payments
  • Other PaymentsOther Payments
Bank details/ Documents

Bank details/ Documents

  • Document CenterDocument Center
  • Bank details & DocumentsBank details & Documents
  • Tax Invoice CertificateTax Invoice Certificate
Do Not Call Service

Do Not Call Service

  • Do Not Call ServiceDo Not Call Service
Your Things

Your Things

  • Your OrdersYour Orders
  • Hamara Mall OrdersHamara Mall Orders
Rewards

Rewards

  • Explore Bajaj PrimeExplore Bajaj Prime
  • Explore RewardsExplore Rewards
  • Buy Deals & Gift cardsBuy Deals & Gift cards
Partners

Partners

  • Fixed Deposit (IFA) PartnerFixed Deposit (IFA) Partner
  • Loan (DSA) PartnerLoan (DSA) Partner
  • Debt Management PartnerDebt Management Partner
  • EMI Network PartnerEMI Network Partner
  • Become a MerchantBecome a Merchant
  • Partner Sign-inPartner Sign-in
What's New

What's New

  •  Food & Shopping Food & Shopping
  • Credit Card HubCredit Card Hub
  • ULIP PlansULIP Plans
  • Top Gainers StockTop Gainers Stock
  • Top Losers StockTop Losers Stock
  • Saving PlanSaving Plan
  • Term InsuranceTerm Insurance
  • Easy EMI LoanEasy EMI Loan
Watch Live

Watch Live

  • Live VideosLive Videos
Help and Support
Settings
Update Profile Manage Consent Refer and Earn About Us Important Information Terms of Service Privacy Policy Fair Practice Code Citizen Charter LogOut TICC
Relations Documents Profile Loan Payments

Error

400

We are sorry.

There's nothing here yet.

BACK TO HOMEPAGE
  • Overview
  • Performance
  • Fundamentals
  • Financials
  • Technical summary
  • Shareholding pattern
  • About
  • View more stocks
  • All stocks
  • Top gainers
  • Top losers
  • FAQs

GLENMARK PHARMACEUTICALS

GLENMARK

NSE

BSE

Pharmaceuticals

₹ 1430.1

-10.0 -0.69%

OPEN DEMAT ACCOUNT

Stock price as on May 22 2025 10:49 AM

Stock performance

Performance

Company fundamentals

Fundamentals

Company financials

Financials

Stock technical summary

Technical summary

Company shareholding pattern

Shareholding pattern

About

About {Company_Name}

Similar stocks

Similar stocks

FAQs

FAQs

Performance Graph
YTD 1 Week 1 Months 3 Months 6 Months 1 Year -0.69% 1.32% 4.92% 6.46% -2.05% 38.83%

Glenmark Pharmaceuticals stock performance

Today’s low

1417.2

Today’s high

1439.7

1430.1

52 week low

1000.0

52 week high

1830.95

1427.4

Open

1427.4

Previous close

1440.1

Share volume

1168.0

Total traded value (Lakh)

16.67

Upper circuit

1584.1

Lower circuit

1296.1

Stock performance

This data indicates the stock's performance over a specific period, measured by tracking its price movements.

<p><b>Open</b></p> <p style="text-align: left;">The price at which a stock begins trading at the start of the trading day.<br /> </p> <p> </p> <p><b>Previous close</b></p> <p style="text-align: left;">The price at which a stock ended trading on the previous day.<br /> </p> <p> </p> <p><b>Share volume</b></p> <p style="text-align: left;">The total number of shares  traded during a specific period, typically within a trading day.</p> <p> </p> <p><b>Trade value</b></p> <p>The total value of all trades made during a specific period.<br /> </p> <p> </p> <p><b>Upper circuit</b></p> <p>The maximum allowed price increase in a stock during a single session, after which trading is temporarily paused.</p> <p> </p> <p><b>Lower circuit</b></p> <p>The maximum allowed price decrease in a stock during a single session, after which trading is temporarily paused.</p> <p> </p>

Glenmark Pharmaceuticals fundamentals

Market cap (Cr)
40637.92
P/E ratio (TTM)
6.67
Book value per share
₹ 0.0
Beta
0.85
Return on equity
6.98
Earnings per share (TTM)
₹ 81.64
Dividend yield
0.17%
Net profit/quarter (Cr)
₹ 413.8

Fundamentals

Understand the common terms associated with a company's stock fundamentals

<p><b>Market cap</b></p> <p>The total value of a company's outstanding shares, calculated by multiplying the current stock price with the number of shares.<br> </p> <p>&nbsp;</p> <p><b>P/E ratio (TTM)</b></p> <p style="text-align: left;">The price-to-earnings ratio, showing how investors value a company by dividing the stock price by earnings per share (EPS).<br> </p> <p>&nbsp;</p> <p><b>Book value per share</b></p> <p style="text-align: left;">The value of a company per share, calculated by dividing the company's net assets by the total number of shares.</p> <p style="text-align: left;">&nbsp;</p> <p><b>Beta</b></p> <p>A measure of a stock’s volatility compared to the&nbsp; market:</p> <p>&nbsp;</p> <p>Beta of 1: Stock moves with the market.</p> <p>Beta &gt; 1: More volatile.</p> <p>Beta &lt; 1: Less volatile.</p> <p>&nbsp;</p> <p><b>Return on equity</b></p> <p style="text-align: left;">Indicates how profitable a company is compared to shareholder investment, calculated by dividing net income by shareholders' equity.<br> </p> <p>&nbsp;</p> <p><b>Earnings per share (TTM)</b></p> <p>The profit earned per share over the past 12 months.<br> </p> <p>&nbsp;</p> <p><b>Dividend yield</b></p> <p>The return on investment from dividends, calculated by dividing the annual dividend by the current share price.</p> <p>&nbsp;</p> <p><b>Net profit/quarter</b></p> <p>The profit a company makes in a quarter after all expenses and taxes are deducted.</p> <p>&nbsp;</p>

Glenmark Pharmaceuticals financials

(Values in Cr)

Revenue

Net income

Revenue

Particulars

202412 (₹ value in crores)

Revenue

2208.84

Operating expense

1820.98

Net income

413.8

Net profit margin

18.73%

Earnings per share

14.66

EBITDA

623.11

Effective tax rate

26.03
Revenue

Particulars

202409 (₹ value in crores)

Revenue

2594.89

Operating expense

1924.12

Net income

595.06

Net profit margin

22.93%

Earnings per share

21.09

EBITDA

861.7

Effective tax rate

25.15
Revenue

Particulars

202406 (₹ value in crores)

Revenue

2296.88

Operating expense

1766.87

Net income

453.73

Net profit margin

19.75%

Earnings per share

16.08

EBITDA

686.75

Effective tax rate

26.61
Revenue

Particulars

202403 (₹ value in crores)

Revenue

2077.13

Operating expense

1786.57

Net income

4613.7

Net profit margin

222.11%

Earnings per share

163.5

EBITDA

6430.64

Effective tax rate

26.7
Revenue

Particulars

202312 (₹ value in crores)

Revenue

1304.16

Operating expense

1674.12

Net income

-20.41

Net profit margin

-1.56%

Earnings per share

-0.72

EBITDA

49.25

Effective tax rate

72.96

(Values in Cr)

Revenue

Net income

Revenue Annual

Particulars

202403 (₹ value in crores)

Revenue

7649.76

Operating expense

7128.73

Net income

5167.29

Net profit margin

67.54%

Earnings per share

183.13

EBITDA

7480.01

Effective tax rate

26.18
Revenue Annual

Particulars

202303 (₹ value in crores)

Revenue

8019.67

Operating expense

7138.86

Net income

1208.77

Net profit margin

15.07%

Earnings per share

42.84

EBITDA

1962.84

Effective tax rate

23.1
Revenue Annual

Particulars

202203 (₹ value in crores)

Revenue

8017.38

Operating expense

6849.1

Net income

1997.79

Net profit margin

24.91%

Earnings per share

70.8

EBITDA

2733.18

Effective tax rate

14.53
Revenue Annual

Particulars

202103 (₹ value in crores)

Revenue

7450.91

Operating expense

6094.3

Net income

1649.45

Net profit margin

22.13%

Earnings per share

58.46

EBITDA

2360.48

Effective tax rate

15.14
Revenue Annual

Particulars

202003 (₹ value in crores)

Revenue

6491.2

Operating expense

5803.33

Net income

1354.55

Net profit margin

20.86%

Earnings per share

48.0

EBITDA

1929.57

Effective tax rate

11.73

Financials

<p><b>Quarterly</b>: Months listed along the bottom of the graph represent a quarter.</p> <p><b>Annual</b>: Months listed along the bottom of the graph represent a financial year.<br /> </p>

ROE

ROCE

Consolidated Ratios

Particulars (annual)

Mar 24 (₹ value in crores)

Book value per share

278.11

Return on Equity (ROE)

-50.87

Return on Capital Employed (ROCE)

12.05

Total debt to equity ratio

0.34

EBITDA margin

17.22
Consolidated Ratios

Particulars (annual)

Mar 24 (₹ value in crores)

Book value per share

335.75

Return on Equity (ROE)

7.43

Return on Capital Employed (ROCE)

9.75

Total debt to equity ratio

0.46

EBITDA margin

16.56
Consolidated Ratios

Particulars (annual)

Mar 24 (₹ value in crores)

Book value per share

322.03

Return on Equity (ROE)

14.36

Return on Capital Employed (ROCE)

15.77

Total debt to equity ratio

0.55

EBITDA margin

20.26
Consolidated Ratios

Particulars (annual)

Mar 24 (₹ value in crores)

Book value per share

250.37

Return on Equity (ROE)

14.77

Return on Capital Employed (ROCE)

14.7

Total debt to equity ratio

0.75

EBITDA margin

19.91
Consolidated Ratios

Particulars (annual)

Mar 24 (₹ value in crores)

Book value per share

215.14

Return on Equity (ROE)

13.29

Return on Capital Employed (ROCE)

13.7

Total debt to equity ratio

0.8

EBITDA margin

17.77

ROE

ROCE

Satandalone Data

Particulars (annual)

Mar 24 (₹ value in crores)

Book value per share

814.01

Return on Equity (ROE)

6.98

Return on Capital Employed (ROCE)

9.75

Total debt to equity ratio

0.1

EBITDA margin

30.54
Satandalone Data

Particulars (annual)

Mar 24 (₹ value in crores)

Book value per share

633.57

Return on Equity (ROE)

9.12

Return on Capital Employed (ROCE)

10.79

Total debt to equity ratio

0.2

EBITDA margin

29.84
Satandalone Data

Particulars (annual)

Mar 24 (₹ value in crores)

Book value per share

593.21

Return on Equity (ROE)

10.42

Return on Capital Employed (ROCE)

10.93

Total debt to equity ratio

0.24

EBITDA margin

28.29
Satandalone Data

Particulars (annual)

Mar 24 (₹ value in crores)

Book value per share

524.84

Return on Equity (ROE)

11.77

Return on Capital Employed (ROCE)

12.39

Total debt to equity ratio

0.26

EBITDA margin

31.19
Satandalone Data

Particulars (annual)

Mar 24 (₹ value in crores)

Book value per share

468.73

Return on Equity (ROE)

10.76

Return on Capital Employed (ROCE)

11.13

Total debt to equity ratio

0.27

EBITDA margin

28.75

Financials

<p>Months listed along the bottom of the graph represent a financial year.<br /> </p> <p>         </p> <p><b>Consolidated</b>: Data of the entire group of companies.</p> <p><b>Standalone</b>: Data of the single company.<br /> </p>

(Values in Cr)

Consolidated Balance Sheet

Particulars

Mar 24 (₹ value in crores)

Cash and short-term investments

1659.45

14358.62

14358.62

Total Equity

7847.54

Shares Outstanding

282188156

Price to book ratio

1.18

Return on assets (%)

-10.45

Return on capital (%)

-16.99
Consolidated Balance Sheet

Particulars

Mar 24 (₹ value in crores)

Cash and short-term investments

1160.29

19371.67

19371.67

Total Equity

9839.25

Shares Outstanding

282168156

Price to book ratio

0.73

Return on assets (%)

1.53

Return on capital (%)

2.1
Consolidated Balance Sheet

Particulars

Mar 24 (₹ value in crores)

Cash and short-term investments

1411.51

17083.28

17083.28

Total Equity

9438.12

Shares Outstanding

282168156

Price to book ratio

0.75

Return on assets (%)

5.51

Return on capital (%)

7.18
Consolidated Balance Sheet

Particulars

Mar 24 (₹ value in crores)

Cash and short-term investments

1139.15

15603.57

15603.57

Total Equity

7064.27

Shares Outstanding

282168156

Price to book ratio

0.89

Return on assets (%)

6.21

Return on capital (%)

8.25
Consolidated Balance Sheet

Particulars

Mar 24 (₹ value in crores)

Cash and short-term investments

1111.24

14684.8

14684.8

Total Equity

6070.11

Shares Outstanding

282168156

Price to book ratio

0.44

Return on assets (%)

5.28

Return on capital (%)

7.35

(Values in Cr)

Standalone Balance Sheet

Particulars

Mar 24 (₹ value in crores)

Cash and short-term investments

129.15

27414.39

27414.39

Total Equity

22970.62

Shares Outstanding

282188156

Price to book ratio

1.18

Return on assets (%)

18.84

Return on capital (%)

21.87
Standalone Balance Sheet

Particulars

Mar 24 (₹ value in crores)

Cash and short-term investments

93.79

24585.92

24585.92

Total Equity

17877.46

Shares Outstanding

282168156

Price to book ratio

0.73

Return on assets (%)

4.91

Return on capital (%)

5.75
Standalone Balance Sheet

Particulars

Mar 24 (₹ value in crores)

Cash and short-term investments

29.63

22914.48

22914.48

Total Equity

16738.58

Shares Outstanding

282168156

Price to book ratio

0.75

Return on assets (%)

8.71

Return on capital (%)

9.79
Standalone Balance Sheet

Particulars

Mar 24 (₹ value in crores)

Cash and short-term investments

15.78

20617.52

20617.52

Total Equity

14809.5

Shares Outstanding

282168156

Price to book ratio

0.89

Return on assets (%)

8.0

Return on capital (%)

8.95
Standalone Balance Sheet

Particulars

Mar 24 (₹ value in crores)

Cash and short-term investments

88.25

18951.59

18951.59

Total Equity

13226.26

Shares Outstanding

282168156

Price to book ratio

0.44

Return on assets (%)

7.14

Return on capital (%)

8.06

Financials

<p>Months listed along the bottom of the graph represent a financial year.</p> <p> </p> <p><b>Consolidated</b>: Data of the entire group of companies.</p> <p><b>Standalone</b>: Data of a single company.<br /> </p>

(Values in Cr)

Net income

Net change

Consolidated Cash Flow

Particulars

Mar 24 (₹ value in crores)

569.18

Cash from operations

782.04

Cash from investing

4560.89

Cash from financing

-3906.12

Net change in cash

389.32

Free cash flow

1680.42
Consolidated Cash Flow

Particulars

Mar 24 (₹ value in crores)

868.45

Cash from operations

1265.93

Cash from investing

-528.49

Cash from financing

-77.45

Net change in cash

19.44

Free cash flow

1873.69
Consolidated Cash Flow

Particulars

Mar 24 (₹ value in crores)

1441.24

Cash from operations

1667.09

Cash from investing

-333.28

Cash from financing

-520.49

Net change in cash

254.88

Free cash flow

2457.21
Consolidated Cash Flow

Particulars

Mar 24 (₹ value in crores)

1382.47

Cash from operations

1641.45

Cash from investing

-675.23

Cash from financing

-441.77

Net change in cash

14.19

Free cash flow

2416.21
Consolidated Cash Flow

Particulars

Mar 24 (₹ value in crores)

1096.07

Cash from operations

1859.36

Cash from investing

-783.51

Cash from financing

-444.66

Net change in cash

173.99

Free cash flow

2791.78

(Values in Cr)

Net income

Net change

Standalone Cash Flow

Particulars

Mar 24 (₹ value in crores)

7000.74

Cash from operations

375.64

Cash from investing

3197.19

Cash from financing

-2666.44

Net change in cash

35.29

Free cash flow

570.76
Standalone Cash Flow

Particulars

Mar 24 (₹ value in crores)

1571.87

Cash from operations

1890.48

Cash from investing

-431.46

Cash from financing

-978.49

Net change in cash

64.09

Free cash flow

2080.1
Standalone Cash Flow

Particulars

Mar 24 (₹ value in crores)

2337.44

Cash from operations

1606.78

Cash from investing

-896.92

Cash from financing

-305.12

Net change in cash

14.02

Free cash flow

1770.13
Standalone Cash Flow

Particulars

Mar 24 (₹ value in crores)

1943.75

Cash from operations

1579.25

Cash from investing

-1235.23

Cash from financing

-80.79

Net change in cash

-72.6

Free cash flow

1790.72
Standalone Cash Flow

Particulars

Mar 24 (₹ value in crores)

1534.64

Cash from operations

1918.46

Cash from investing

-1607.38

Cash from financing

-139.41

Net change in cash

-167.68

Free cash flow

2037.66

Financials

<p>Months listed along the bottom of the graph represent a financial year.</p> <p> </p> <p><b>Consolidated</b>: Data of the entire group of companies.</p> <p><b>Standalone</b>: Data of a single company.<br /> </p>

Company name

Price

P/E

P/B

Market cap

52 week low/high

38.57

20.74

2.1

295.57

34.11 / 77.7

121.65

15.21

1.22

1281.83

92.25 / 184.95

1454.5

22.28

3.76

117471.3

1310.05 / 1702.0

299.95

24.85

3.04

882.78

145.0 / 449.0

₹38.57

23.23

6.55

295.57

34.11 / 77.7

₹684.05

38.91

6.05

1977.63

548.05 / 861.4

₹7920.85

118.13

29.14

19802.13

5415.55 / 9199.0

₹121.65

18.57

1.21

1281.83

92.25 / 184.95

Glenmark Pharmaceuticals technical summary

1440.10.27
4
12
Bullish
1435.9
1427.6
1425.1
1420.4
1419.8
1425.4
1445.8
1424.2
1442.6
1426.4
1423.1
1410.5
1400.4
1427.6
1450.1
1536.7
1438.9
PIVOT
First support1420.2
Second support1404.2
Third support₹1385.5
RSI53.46
MACD5.31%
Commodity Channel Index (CCI)₹96.81
First resistance1454.9
Second resistance1473.6
Third resistance-1489.6
ADX16.34
Williams % R-30.16
Date2025-05-20
Same day509383
Week278617
Month451280
1 year
38.83
3 years
52.18
Price change analysis
-1.32%
Over 1 month
-4.92%
Over 3 month
-6.46%
Over 6 month
--2.05%
Over 3 year
52.18%
Over 6 year
33.1%

Glenmark Pharmaceuticals shareholding pattern

Holding %

Public

15.59%

Promoter holdings

46.64%

FII

23.15%

DII

14.6%

Promoter shares

0%

Promoter shares

Saldanha Family Trust

Hdfc Mutual Fund - Hdfc Nifty Large Midcap 250 Ind

Mirae Asset Arbitrage Fund

Government Pension Fund Global

Smallcap World Fund, Inc

Ashish Dhawan

Invesco India Midcap Fund

Ellipsis Partners Llc

3p India Equity Fund 1

Blanche Elizabeth Saldanha

Glenn Mario Saldanha

Cherylann Maria Pinto

Robin Joseph Pinto

Neha Saldanha

Share

Category

128241936
(45.45)%

Shareholding of Promoter and Promoter Group

12047156
(4.27)%

Public Shareholding

9951586
(3.53)%

Public Shareholding

9162665
(3.25)%

Public Shareholding

9068639
(3.21)%

Public Shareholding

5000000
(1.77)%

Public Shareholding

3989487
(1.41)%

Public Shareholding

3137593
(1.11)%

Public Shareholding

2865000
(1.02)%

Public Shareholding

1114327
(0.39)%

Shareholding of Promoter and Promoter Group

994689
(0.35)%

Shareholding of Promoter and Promoter Group

758485
(0.27)%

Shareholding of Promoter and Promoter Group

497500
(0.18)%

Shareholding of Promoter and Promoter Group

26000
(0.01)%

Shareholding of Promoter and Promoter Group

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977. The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets. The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology. Its branded generics business has a significant presence in markets across emerging economies including India. The company has 14 manufacturing facilities across US, India, Argentina, Czech Republic and Switzerland. The generics business services the requirements of developed markets like the US and Western Europe. The API business sells products in over 80 countries including the US, various countries in the EU, South America and India. In the year 1979, the company entered dermatology market with the launch of 'Candid Cream'. In the year 1980, they started exporting their products. In the year 1983, the company commissioned their first manufacturing facility at Nasik in Maharashtra. In the year 1984, they established R&D department at Nasik Plant. In the year 1987, they launched Ascoril. In the year 1989, the company started operations in Afghanistan, Sri Lanka, Kenya and Mauritius. In the year 1982, the company expanded the Nashik plant by acquiring the adjacent plot to include the R&D Department as well as increase in installed production capacity. In the year 1996, the company incorporated a wholly owned subsidiary company namely, Glenmark Exports Pvt Ltd to consolidate their position in international business. In the year 1999, they started marketing their products in Brazil. In the year 2000, they came out with the public issue. They entered in diabetes segment. Also, they acquired three brands from Lyka Labs. In the year 2001, the company launched API manufacturing business. In the year 2002, they acquired an API manufacturing facility at Ankleshwar, Gujarat from Glaxosmithkline Pharmaceuticals Ltd. In the year 2004, the company entered their first out-licensing deal for discovery R&D with Forest Laboratories for Oglemilast, their CIPD/asthma molecule. They acquired Laboratories Klinger; Brazil together with their ANVISA approved manufacturing facility inorder to expand their operations in the Latin American markets. They commissioned their own manufacturing facility in Goa to service exports to regulated markets, namely USA. In the year 2005, the company launched commercial sales front-end in the US. They commissioned a new manufacturing facility at Baddi, Himachal Pradesh. They entered collaborative agreement on Oglemilast with Teijin Pharma for the Japan region. Also, they announced collaborative agreement with Napa Pharmaceuticals Inc, for their anti-diarrheas compound Crofelemer. The company acquired Servycal S A, a marketing company in Argentina with strengths in oncology. Also, they acquired Bouwer Bartlett Pty Ltd, a sales and marketing company in South Africa. In the year 2006, the company signed out-licensing deal in discovery R&D with Merck KGaA, Germany for their diabetes molecule, Melogliptin. Their lead molecule Oglemilast (GRC 3886) entered Phase II clinical trials. In the year 2007, the company acquired Medicamenta, a marketing and manufacturing company in the Czech Republic. Their molecule GRC 6211 for the potential treatment of pain, including osteo-arthritis pain out-licensed to Eli Lily. They received MHRA, UK approval for their semi-solid manufacturing plant at Baddi. In the year 2008, the company initiated Phase II-b for Oglemilast (GRC 3886) in Asthma. They completed pre-clinical development for initiating Phase I trials for GBR 500, a monoclonal antibody for inflammation. The company's molecule for Rheumatoid Arthritis, GRC 4039, entered Phase I trials. They re-organized their business and incorporated Glenmark Genrics Ltd as a subsidiary company. They received USFDA approval for the state-or-the-art semi-solids manufacturing plant at Baddi. In the year 2009, the company's molecule for neurophatic pain, osteoarthritis, completed the Phase I trials. During the year 2009-10, the company incorporated a subsidiary company, namely Glenmark Generics B.V., Netherlands. In the year 2010, Crofelemer, a first-in-class anti-diarrhoeal molecule completed phase 3 trials. They received the final approval for Pramipexole Dihydrochloride tablets from the USFDA. Glenmark Generics entered into an exclusive licensing agreement with Par Pharmaceuticals, USA to market Ezetimibe. The company and Sanofi-Aventis signed license agreement to grant Sanofi-Aventis a license for the development and commercialization of novel agents to treat chronic pain. They launched 'Prasugrel', a revolutionary new anti-platelet drug for the management of Acure Coronary Syndrome with PCT (Precutaneous Coronary Intervention) for the first time in India. During the year 2010-11, the company has incorporated a subsidiary company namely, Glenmark Arzneimittel GmbH, Germany. In October 2010, the company won the Frost and Sullivan Award for 'Indian Innovator Pharmaceutical Company of the year' in October 2010. The company was chosen as the 'Best Company Across Emerging Markets' 2011, and recognized for the 'Best Overall Pipeline' 2011 by SCRIP, the largest selling and most respected pharmaceutical magazine in the world. In 2012, Forest Laboratories and Glenmark Signed Development Agreement for Worldwide Collaboration on Novel Agents to treat Chronic Inflammatory Conditions. Glenmark Generics announces the settlement of Paragraph IV litigation with Janssen Pharmaceuticals, Inc. Glenmark Generics receives tentative approval for zolmitriptan orally disintegrating tablets. The International Centre for Dispute Resolution ruled in favor of Glenmark on arbitration claim against Napo. In 2013, Glenmark announces launch of Hydrocortisone Butyrate cream in the US. Glenmark announces a new Discovery and the Initiation of IND enabling studies of a novel monoclonal antibody targeting OX40. The USFDA approves the companies Crofelemer 125 mg delayed-release tablets for the symptomatic relief of diarrhea in patients with HIV/AIDS on anti-retroviral therapy (ART). Glenmark Generics receives ANDA approval for Mupirocin Calcium Cream USP 2%. Atovaquone Prognanil (Malarone) patent revoked & Glenmark launches first UK generic. Glenmark discovers IND enabling studies of a novel monoclonal antibody. In 2014, Glenmark merge its subsidiaries i.e. Glenmark Generics Ltd. ('GGL') and Glenmark Access Ltd. ('GAL') with GPL. Glenmark enters Oncology with the Discovery and the Initiation of IND enabling studies of an innovative bi-specific antibody. Glenmark Pharmaceuticals inaugurates new Antibody Manufacturing Facility in La Chaux-de-Fonds, Switzerland. US Food & Drug Administration (USFDA) has granted Glenmark its final acceptance for abbreviated new drug approval (ANDA) to the company. Glenmark Pharma receives $5 mn from Sanofi as milestone payment from Sanofi on a collaboration of its VLA2 (alpha2-beta l) integrin monoclonal antibody. Glenmark Generics gets USFDA nod for skin infection cream. In 2015, Glenmark Pharmaceuticals Ltd announces approval and launch of Ashlyna TM Extended - Cycle Oral Contraceptive Tablets in the US. Glenmark Pharmaceuticals Ltd announces approval and launch of Trandolapril & Verapamil Hydrochloride (HCI). Glenmark Pharma gets US FDA nod for Salmecort MDI Inhaler in Russia. The Cabinet Committee on Economic Affairs (CCEA) headed by PM approves the foreign investment proposals of two pharma majors Glenmark Pharmaceuticals and Aurobindo Pharma worth Rs 4,187 crore. Glenmark Pharmaceuticals Ltd. has certified approving the Scheme of Arrangement of Glenmark Generics Ltd. and Glenmark Access Ltd. with Glenmark Pharmaceuticals Ltd. Glenmark announces Strategic Development & Licensing Agreement with Celon, Poland for generic Seretide Accuhaler in Europe. Glenmark Pharmaceuticals receives tentative ANDA approval for Lacosamide Tablets, 50 mg, 100 mg, 150 mg and 200 mg. Glenmark Pharmaceuticals receives ANDA approval for Clotrimazole and Betamethasone Dipropionate Cream USP, 1%: 0.05%. Glenmark Pharmaceuticals has entered into a settlement agreement with Forest Laboratories, LLC, Forest Laboratories Holdings, Ltd., and Royalty Pharma. During the year, the company received approval for generic Seretide in Russia. On 19 September 2016, Glenmark Pharmaceuticals, Inc., USA announced that it has entered into a strategic Development, License and Commercialization Agreement with Particle Sciences, Inc. to develop and market a generic version of Celgene's ABRAXANE product - paclitaxel protein (albumin)-bound particles for injectable suspension. As per the terms of the agreement, Glenmark has obtained Global Exclusive Marketing and Distribution rights of the product upon commercialization. Particle Sciences will develop this product exclusively for Glenmark, and shall receive certain milestone payments during various stages of the product's development from Glenmark, including royalties on sales. On 12 December 2016, Glenmark Pharmaceuticals Inc., USA announced the availability of ezetimibe, the first and only generic version of ZETIA (Merck) in the United States for the treatment of high cholesterol. The availability of ezetimibe is the result of a licensing partnership with Par Pharmaceutical, an Endo International plc operating company, with whom Glenmark will share profits. Glenmark and its partner, Endo will be entitled to 180 days of generic drug exclusivity for ezetimibe as provided for under Section 505 (j) (5) (B) (iv) of the FD&C Act. On 19 December 2016, Glenmark Pharmaceuticals announced its strategic blueprint to transition into an innovation-led global pharmaceutical organization over the next decade. The Blueprint conveys the company's greater business alignment expanding generics to prioritizing research and development efforts in three key therapeutic areas: oncology, respiratory and dermatology. The innovative oncology pipeline, with candidates targeting multiple tumors, is the top priority with the greater promise to deliver novel, first-in-class molecules and help Glenmark evolve into a fully commercialized, innovation-led pharmaceutical company. The strategic blueprint also outlines aggressive plans to increase Glenmark's presence worldwide by strengthening focus on complex generics including injectables and expanding its manufacturing footprint. On 2 March 2017, Glenmark Pharmaceuticals announced that its US subsidiary Glenmark Pharmaceuticals Inc., USA, and Evestra, Inc. have completed a strategic development, license and commercialization agreement to develop and market a generic version of Merck's & Co.'s NuvaRing product - etonogestrel/ethinyl estradiol vaginal ring - designed to allow women access to a more affordable birth control option. Development on the vaginal ring product is currently under way and the two companies expect to file an Abbreviated New Drug Application (ANDA) in fiscal 2019. Evestra will develop this product exclusively for Glenmark for the US market, and will receive certain milestone payments during various stages of the product's development, including royalties on net sales. Glenmark has secured exclusive marketing and distribution rights for the product, including an option to commercialize two additional Evestra vaginal ring products, for the US market. On 30 March 2017, Glenmark Pharmaceuticals announced positive results for GSP 301, an investigational fixed-dose combination of mometasone furoate (25 mcg) and olopatadine hydrochloride (665 mcg) administered twice daily as a nasal spray being studied for the treatment of seasonal allergic rhinitis. These results are from a recently completed Phase 3 trial assessing the efficacy and safety of GSP 301 combination therapy versus mometasone, olopatadine or placebo. On 14 December 2017, Glenmark Pharmaceuticals announced that it met its primary clinical endpoint in a Phase 3 study evaluating the safety of Ryaltris, an investigational fixed-dose combination nasal spray, in perennial allergic rhinitis (PAR). Ryaltris has conditionally accepted as the brand name for GSP 301 Nasal Spray by the US Food & Drug Administration (FDA). Glenmark plans to submit the company's first new drug application (NDA) to the FDA for Ryaltris for the treatment of patients with seasonal allergic rhinitis (SAR) in the first quarter of CY 2018. On 22 February 2018, Glenmark Pharmaceuticals announced that it has entered into an exclusive agreement with South Korea's Sam Chun Dang Pharm. Co. Ltd. (SCD), to develop, manufacture and market a portfolio of ophthalmic products in the US and Canada. Under this agreement, these products will be developed and manufactured by SCD in South Korea. Glenmark will seek all market authorizations and commercialize the products in North America. On 4 April 2018, Glenmark Pharmaceuticals and Helsinn Group (Helsinn), a Swiss pharmaceutical group focused on building quality cancer care products, announced that they have entered into an exclusive licensing agreement to introduce AKYNZEO in India and Nepal. AKYNZEO, an oral fixed combination of netupitant 300mg and palonosetron 0.5mg in capsule form, is used for prevention of Chemotherapy-induced Nausea and Vomiting (CINV). The licensing agreement with Glenmark for AKYNZEO represents Helsinn's first such agreement in India. Glenmark will have exclusive marketing rights for AKYNZEO in India and Nepal. On 22 May 2018, Glenmark Pharmaceuticals announced that the company has submitted a New Drug Application (NDA) to the US Food & Drug Administration (FDA) for its leading respiratory pipeline candidate Ryaltris, an investigational fixed-dose combination nasal spray of an antihistamine and a steroid, as a treatment for seasonal allergic rhinitis (SAR) in patients 12 years of age and older. Ryaltris (olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg), formerly GSP 301 Nasal Spray, has been conditionally accepted by the FDA as the brand name. On 19 June 2018, Glenmark Pharmaceuticals announced that the US Food & Drug Administration provided its first supplemental Abbreviated New Drug Applications (ANDA) approval for the company's manufacturing facility in Monroe, North Carolina. The approval covers: Atovaquone and Proguanil Hydrochloride Tablets, 250 MG/100 MG and 62.5 MG/25 MG, a generic version of GlaxoSmithKline's Malarone (atovaquone and proguanil hydrochloride) Tablets. The Monroe, North Carolina facility is Glenmark's first manufacturing site in the US, designed to manufacture a variety of fixed dose pharmaceutical formulations. Glenmark has invested more than $100 million into the facility with plans for further expansion in the coming years. At peak capacity, the site is anticipated to produce 300-400 million tablets and capsules, 20-25 million vials and pre-filled syringes and 25-30 million ampoules for inhaled formulations. During the F.Y. 2017-18 Glenmark Pharmaceuticals Singapore Pte. Ltd. was formed as the wholly owned subsidiary of the company In FY18, Glenmark was granted approval of 21 Abbreviated New Drug Applications (ANDA), comprising 18 final approvals and three tentative approvals. Notable approvals include Aprepitant Capsules USP, Atomoxetine Capsules USP, Nitroglycerin Sublingual Tablets and Propafenone Hydrochloride Extended-Release Capsules USP. The Company filed a total of 16 ANDA applications with the US FDA throughout the fiscal year. During the year 2018, Glenmark launched Dermikelp, VWash Plus, Tacroz and Tacroz F in Zambia; Tacroz and Telma H in Tanzania; Ascoril D, Teneligliptin and its combination with Metformin in Mauritius, Momate F in Uganda and Sertaconazole (Onabet) in Sudan. During the year 2018, Glenmark launched Tacroz, Dosetil and Momate NS in Philippines; Momate NS, Dermikelp and VWash in Malaysia and Konzert in Cambodia in the Asia region. As on March 31 2018, the Company has filed over 370 Global DMFs in various markets, including 103 USDMFs, 28 CEPs, 40 EU- DMFs, 22 Canadian DMFs, 12 Japan DMFs, 13 Australian DMFs and other DMFs in various Rest-of-the-World (ROW) countries. During the year 2018, NebZmart, NebZsol and Vocety were launched in Brazil. In Colombia, the Company strengthened its dermatology portfolio and introduced Glenpalene, Glenpalene C, Dermotil S, Glencort, Butemax and Clotridid. Momate AZ nasal spray was launched in the Caribbean region and Glenmark is the first generic alternative in the market offering this unique combination. In FY18, Momate Rhino Advance, a unique combination of mometasone + azelastine nasal spray on the local market, was launched in Uzbekistan and is indicated for the treatment of patients with seasonal allergic rhinitis. Momat Rino 60 and 120 doses nasal sprays were also launched in Uzbekistan. During the year, Glenmark launched Glenspray (mometasone) 50 mcg/120 doses and Glenspray (mometasone) 50 mcg/60 doses in Ukraine. During the year 2018, Glenmark also successfully concluded the US FDA audit of the API plant at Mohol and is awaiting the EIR from the agency. During the year 2018-19, the Company acquired 100% stake in Zorg Laboratories Private Limited (Zorg) for an aggregate consideration of 5 lacs before adjustments and subject to legal and financial due diligence. Subsequently, name of Zorg was changed to Glenmark Life Sciences Limited (GLS). The shareholders of the Company approved the transfer of its Active Pharmaceuticals Business (API) to GLS by passing a resolution through postal ballot. During the FY2019, the Company had entered into a collaboration with leading, home-grown private equity firm True North Enterprise Private Limited (True North') and transferred its Orthopaedic and Pain management business valued at Rs 635 crore to Integrace Private Limited, a subsidiary of True North. Integrace will market the product portfolio in India and Nepal. As on 31 March 2019,the company has 42 subsidiary companies under its roof. The Company filed a total of 13 ANDAs with the USFDA during the financial year. In FY 2018-19, Glenmark was granted approval for 25 Abbreviated New Drug Applications (ANDA), comprising of 20 final approvals and 5 tentative approvals. During the year, the company bagged CII Safety Health and Environmental Excellence and Innovation Award 2018 for the Indore facility. During the FY2020,the Company had entered into Business Transfer Agreement with Integrace Private Limited for transfer Company's Gynaecology business, valued at Rs 115 crore. During the year, the Company entered into definitive agreement with Hindustan Unilever Limited for divestment of VWash franchise comprising VWash Plus Intimate Hygiene Wash, VWash WOW, VWash Plus Bikini Line, VWash Plus wipes and other such assets globally including the associated trademarks, brand names and certain business contracts. It launched a globally researched innovator molecule, Remogliflozin in FY 2019. As on 31 March 2020, the company has 44 subsidiary companies under roof. It introduced a fixed-dose combination of Remogliflozin Etabonate and Vildagliptin in 2020. It also launched a fixed-dose combination of Remogliflozin+Metformin under the brand names Remo-M and Remo-Zen M. Glenmark Life Sciences Limited, a wholly owned subsidiary of the Company on 16th April 2021 has filed a draft red herring prospectus with the Securities and Exchange Board of India for an initial public offer, comprising of a fresh issue of up to Rs. 11,600 million and an offer for sale of up to 7,305,245 equity shares of Rs. 2 each of Glenmark Life Sciences Limited, by Glenmark Pharmaceuticals Limited. The !PO will be subject to market conditions, receipt of applicable approvals and other considerations. In the fiscal year 2020-21, Glenmark was granted approval of 14 ANDAs comprised of 10 final approvals and 4 tentative approvals. Additionally, it was granted approval on a Prior Approval Supplement (PAS) for the 0.25 mg strength for Fingnolimod Capsules. Notable approvals include: Sirolimus Tablets, Tacrolimus Capsules USP, Topiramate Extended-Release Capsules USP, Chlorpromazine Hydrochloride Tablets USP and Diltiazem Hydrochloride Extended-Release Capsules USP. The Company filed a total of 7 ANDAs with the USFDA in FY21 and plan to file 18-20 ANDAs in FY22 including 5-6 filings which got delayed in FY21 due to the pandemic. During 2021, its subsidiary, Ichnos Sciences signed a licensing agreement with Almirall SA for the IL-1RAP antagonist ISB 880 for an upfront payment of EUR 20.8 Million. It received approval for 14 ANDAs that comprised 10 final approvals and 4 tentative approvals. It launched 10 new products in FY 2020-21. On 30th April, 2021, the Company made a strategic investment of Rs. 400 million in ABCD Technologies LLP . During the year 2022, Company received US FDA's NDA approval for novel Ryaltris-AZ as a novel fixed dose with a steroid of Mometasone Furoate and Azelastine for the treatment of allergic rhinitis in adults and paediatric patients 12 years of age and older. It launched Tiotropium Bromide Dry Powder Inhaler (DPI) in UK. It launched Tavulus in Spain and Tiotropium in Germany. It also launched Beclometasone to provide asthma patients access to a high-quality, cost-effective inhaler. It launched Glendes in Malaysia for treatment of minor cases of allergy. In Brazil, it launched Salbutamol to relieve symptoms of asthma and chronic obstructive pulmonary disease (COPD) such as coughing, wheezing and feeling breathless. It launched Canditral- SB in India to treat fungal infections of the mouth, throat, toenails, fingernails or lungs. To treat the symptoms of LennoxGastaut Syndrome (seizures), it launched Rufinamide tablets in the USA. It collaborated with Canadian biotech firm SaNOtize Research & Development Corp. to manufacture, market and distribute its breakthrough Nitric Oxide Nasal Spray (NONS) for COVID-19 treatment in India and other Asian markets including Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam. It launched NONS under the brand name FabiSpray in February 2022, after receiving manufacturing and marketing approval from the Drugs Controller General of India (DCGI) as part of the accelerated approval process. Ichnos Sciences Inc., a subsidiary of Glenmark completed a EUR ~21 Million exclusive licensing agreement for the IL-1RAP antagonist ISB 880. Remogliflozin, Vildagliptin, Metformin, a Fixed Dose Combination (FDC) was launched during the year to enhance patient access to SGLT2 and DPP4 inhibitors for effective treatment of diabetes. FabiSpray was also launched in Singapore and Hong Kong under the brand name VirX. It introduced India's first Probiotic based product across its dermatology portfolio, such as Elovera Pro Cream and Elovera Pro Lotion. It launched 10 new products in the US taking total marketing portfolio in US 174 generic products authorized for distribution in the U.S. market. It entered into an agreement with AstraZeneca to commercialize its product, Pulmicort Respules in Colombia. Besides this, it entered into exclusive licensing agreement with Lotus International Pte. Ltd. for commercializing Ryaltris in Singapore, Hong Kong and Vietnam. Three new pharmaceutical modules became fully operational at its Ankleshwar facility. During the year 2022-23, in the Respiratory segment, Glenmark became the first company in India to market Indamet - an innovative fixed drug combination of Indaceterol, a long-acting beta-agonist and mometasone, an inhaled corticosteroid, for the treatment of uncontrolled asthma. In the Diabetes segment, it launched sitagliptin under the brand name SITAZIT and its fixed dose combinations with metformin and dapagliflozin respectively; teneligliptin + pioglitazone Fixed-Dose Combination drug for Type 2 Diabetes under the brand name Zita Plus Pio; lobeglitazone 0.5mg, under the brand name LOBG; Fixed-Dose Combination (FDC) of Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) SR under the brand name Zita-PioMet; Lobeglitazone + Metformin under the brand name LOBG-M. In the Cardio-Vascular segment, it launched Sacubitril + Valsartan under the brand name, Sacu V for the treatment of heart failure. New products such as La Shield Pollution Protect, La Shield Probiotic Moisturizer and Scalpe Pro Shampoo contributed to business growth in FY23. Thereafter, in FY23, Glenmark launched 8 new products during the fiscal year 2022-23, consisting of a mix of immediate-release oral solids and an injectable. Notable launches include Ezetimibe Tablets USP; Abiraterone Acetate Tablets USP, 500 mg; Fingolimod Capsules, 0.5 mg; Sodium Phenylbutyrate Tablets USP, 500 mg; Nicardipine Hydrochloride Capsules; Bumetanide Injection, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials; and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials, and Teriflunomide Tablets. It launched first generics, Teriflunomide (Aubagio) Tablets. It got into a distribution agreement with Cediprof for USFDA approved Mixed Amphetamines Immediate-Release Tablets. As of March 31, 2023, Glenmark's marketing portfolio included 183 generic products authorized for distribution in the U.S. market. 4 new products were introduced in the market, including Fenismart(dimetindene) gel and Phelisans (phenasone + lidocaine) ear drops. It launched RYALTRIS in the Malaysian market in 4Q of FY23. In 2024, Company was the first to launch a biosimilar of popular anti-diabetic drug, Liraglutide in India. It partnered with Pfizer to launch Abrocitinib in India under the brand name of 'JABRYUS'. The Company further enhanced its global branded portfolio through in-licensing of Envafolimab for India & RoW markets, and Winlevir for select European markets, the UK and South Africa. The Company and Ichnos Sciences entered in to an alliance - Ichnos Glenmark Innovation (IGI) to accelerate new drug development in cancer treatment. Glenmark sold its 75% stake in Glenmark Life Sciences (GLS) to Nirma Ltd in FY24. Glenmark got into an agreement with BeiGene for marketing & distribution of Tislelizumab & Zanubrutinib in India.

Parent Organisation

Indian Private

NSE Symbol

GLENMARK

Founded

1977

View more stocks

IOL CHEM AND PHARMA LTD

₹86.27

8.98%

GLAXOSMITHKLINE PHARMA LT

₹2984.2

7.09%

CAPLIN POINT LAB LTD.

₹2252.4

5.89%

MARKSANS PHARMA LIMITED

₹250.21

5.67%

SEQUENT SCIENTIFIC LTD.

₹178.73

5.5%

MOREPEN LAB. LTD

₹65.94

4.94%

GLAND PHARMA LIMITED

₹1571.3

4.87%

VENUS REMEDIES LIMITED

₹349.9

4.83%

INFINIUM PHARMACHEM LTD

₹315.0

4.61%

MEGASOFT LTD

₹78.8

4.1%

Popular stocks

Rail Vikas Nigam
Suzlon Energy
NHPC
Yes Bank
TATA Motors
BHEL
HDFC Bank
State Bank of India
TATA Power
TATA Steel
NBCC India
Infosys India
Adani Power
IFCI
Coal India
OLA Electric

What’s trending

Top gainers Top losers 52-week high 52-week low All stocks

All stocks

DYNAMIND

DYNAMIC INDUSTRIES LTD.

120.37

+20.06 +20%

ADDIND

ADDI INDUSTRIES LTD.

80.64

+13.44 +20%

NAHARPOLY

NAHAR POLYFILMS LTD.

262

+41.35 +18.74%

NAHARPOLY

NAHAR POLY FILMS LIMITED

261.99

+40.61 +18.34%

View all

Top gainers

INDUSINDBK

INDUSIND BANK LIMITED

793.9

+23.95 +3.11%

TATASTEEL

TATA STEEL LIMITED

162.69

+1.05 +0.65%

JIOFIN

JIO FIN SERVICES LTD

275.8

+1.45 +0.53%

BHARTIARTL

BHARTI AIRTEL LIMITED

1831.5

+9.00 +0.49%

View all

Top losers

POWERGRID

POWER GRID CORP. LTD.

289.3

-6.85 -2.31%

TRENT

TRENT LTD

5348

-95.50 -1.75%

ITC

ITC LTD

425.5

-7.50 -1.73%

RELIANCE

RELIANCE INDUSTRIES LTD

1406.3

-22.90 -1.60%

View all

Frequently asked questions

What is share price of GLENMARK PHARMACEUTICALS?
<p> As of May 22 2025 10:49 AM, at May 22 2025 10:49 AM, the GLENMARK PHARMACEUTICALS share price stands at Rs.1430.1.</p>
What is the market cap of GLENMARK PHARMACEUTICALS?
<p>As of May 22 2025 10:49 AM, the market cap of GLENMARK PHARMACEUTICALS stands at Rs.40637.92 Cr. <br /> </p>
What is the PE and PB ratio of GLENMARK PHARMACEUTICALS?
<p> The PE and PB ratios of GLENMARK PHARMACEUTICALS is 6.67 ratio and 848.54 ratio as of May 22 2025 10:49 AM.</p>
What is the 52 week high and low of GLENMARK PHARMACEUTICALS?
<p>The 52 week high and low of GLENMARK PHARMACEUTICALS is Rs.1830.95 and Rs.1000.0 as of May 22 2025 10:49 AM.<br /> </p>
How can I buy GLENMARK PHARMACEUTICALS share?
<p>You can easily buy&nbsp;GLENMARK PHARMACEUTICALS shares on&nbsp;the <b>Bajaj Broking</b> platform by opening a Demat account&nbsp;and verifying your KYC documents online. There are no account opening charges for a Demat account with Bajaj Broking.<br> </p>
Show More Text Show Less Text

Related articles

Article 1

How to Buy Shares

Jan 30, 2025

Read More

share-market-timings-in-india 2

Share Market Timings in India

May 15, 2023

Read More

what-is-trading 3

What is Trading

Mar 25, 2025

Read More

what-is-demat-account 4

What is Demat Account: Meaning, Types & Benefits

May 25, 2021

Read More


Related videos

Features and benefits of Demat Account
 
 

Features and benefits of Demat Account

How to open a Demat and Trading account with us
 
 

How to open a Demat and Trading account with us

Stock market basics for beginners
 
 

Stock market basics for beginners

Features and Benefits of a Trading account
 
 

Features and Benefits of a Trading account

Different types of Demat accounts
 
 

Different types of Demat accounts


Related tags

Top gainers
Top losers
52 week high
52 week low
All stocks

You are here

  1. Home
  2. Investments
  3. Glenmark Pharmaceuticals Share Price

Related links

  • Investments
  • Brokerage calculator
  • Demat account
  • Trading account

Disclaimer

*Disclaimer for Bajaj Finance Limited (‘BFL’):

Stock trading business is carried by Bajaj Financial Securities Limited ("BFSL"), a broker and Depository Participant registered with Securities Exchange Board of India and offers various products/services related to Securities market (Securities market products/services). BFL merely facilitates display of data shared by BFSL on its webpage/mobile application. Such data received from BFSL, or any of its service providers is on “as is” basis. BFL does not make any representation or warranty, express or implied, regarding accuracy, completeness of such data displayed herein.

When you opt to avail the Securities market products/services of BFSL by clicking on the BFSL weblink/mobile app, you will be redirected to BFSL's web page/mobile app for initiation and completion of the transaction. You are supposed to exercise independent diligence by reading all the related documents carefully before deciding to invest in Securities market Products/services.

BFL is a Non-Banking Financial Company carrying the business of acceptance of deposits and providing lending solutions to Retail and Corporate customers. BFL does not offer nor advice on Securities market products/services and shall not be liable or responsible for any of your investment decision."
 

**Disclaimer: For Bajaj Financial Securities Limited

Investments in securities market are subject to market risk, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit. All leveraged intraday positions will be squared off the same day. There is no restriction on withdrawal of unutilised margin amount. Trade Recommendations are research-calls provided under the SEBI Research Analyst guidelines. Visit https://www.bajajbroking.in/disclaimer for complete disclaimer.

Securities market Products/services are made available only at the discretion of BFSL and subject to the individual contractual terms and conditions of the respective Securities market products/services. You shall be the sole owner of any decision to invest in any BFSL's Securities market products/services.

Securities market products/services may be withdrawn or amended at any time by BFSL without notice and your recourse in such case would be directly to reach out BFSL at connect@bajajfinserv.in or 1800 833 8888.


Powered by Bajaj Financial Securities Limited (Bajaj Broking)

Go To Top

Application Forms

  • Personal Loan
  • Business Loan
  • Home Loan
  • Gold Loan
  • Insta EMI Card
  • Wallet Care
  • Health Insurance
  • Loan for Doctors
  • Fixed Deposit
  • Loan Against Property
  • Loan for Chartered Accountants
  • Open Demat Account
  • Two-wheeler Loan
  • New Car Finance
  • Used Car Loan
  • Loan Against Car
  • Car Loan Balance Transfer and Top-up
  • Mutual Fund
  • Secured Business Loan
  • Loan for Lawyer

Products Portfolio

Loans

  • Personal Loan
  • Insta Personal Loan
  • Business Loan
  • Home Loan
  • Gold Loan
  • MSME Loan
  • Mortgage Loan
  • Loan Against Property
  • Two & Three Wheeler Loan
  • Education Loan on Property
  • Personal Loan for Self-employed Individuals
  • Two-wheeler Loan
  • New Car Finance
  • Used Car Loan
  • Loan Against Car
  • Car Loan Balance Transfer and Top-up
  • Used Cars and Loan

Insurance

  • Health Insurance
  • Car Insurance
  • Pocket Insurance
  • Investment Plans
  • Appliances Extended Warranty
  • Pocket Subscription

Finance for Professionals

  • Loan for Doctors
  • Loan for Chartered Accountants

Investments

  • Fixed Deposit
  • Open Demat Account
  • Mutual Funds
  • NFO (New Fund Offer)
  • ELSS Mutual Funds
  • Equity Mutual Funds
  • Hybrid Mutual Funds
  • Debt Mutual Funds
  • Multi Cap Mutual Funds
  • Large Cap Mutual Funds
  • Mid Cap Mutual Funds
  • Small Cap Mutual Funds
  • Liquid Mutual Funds
  • Aggressive Hybrid Mutual Funds

Pocket Subscription

  • Mobile Protection Plan
  • Wallet Care
  • Fonesafe Lite
  • Neuro Care Plan
  • Health Prime Max
  • Cpp Road Assist
  • Healthy Body Package

Bajaj Mall

  • Smartphones
  • Mattress
  • Smartwatches
  • Cycles
  • Music & Audio
  • Speakers
  • Water Purifiers
  • Laptops
  • Two-wheeler
  • Washing Machine
  • Televisions
  • Air Conditioner
  • Refrigerators
  • Furniture

Services

  • Sign-in to our Customer Portal (My Account)
  • Manage your Profile
  • Manage your Mandate
  • Manage your Loans
  • Manage your Flexi Loans
  • Manage your Insta EMI card
  • Manage your Fixed Deposit

Wallets & Cards

  • Wallet
  • Bajaj Finserv Insta EMI Card

Value Added Services

  • Credit Pass
  • Gold Rate

Payments

  • All Payments
  • Wallet
  • UPI
  • Mobile recharge
  • Electricity Bill Payment
  • DTH Recharge
  • Loan Repayment
  • Gas Booking
  • Rewards
  • Bajaj Pay FASTAg
  • Bajaj Pay Wallet KYC Upgrade
  • Bajaj Pay FASTAg Registration
  • Bajaj Pay FASTag Replacement
  • Bajaj Pay FASTag Closure
Pre-approved Offers
Offers & Promotions
Article and Insights

Calculators

  • Personal Loan EMI Calculator
  • Home Loan EMI Calculator
  • Home Loan Eligibility Calculator
  • Business Loan EMI Calculator
  • Personal Loan Eligibility Calculator
  • Loan Against Property EMI Calculator
  • Education Loan on Property Calculator
  • FD Calculator
  • Gratuity Calculator
  • Income Tax Calculator
  • Top-up Loan Calculator
  • Part-prepayment Calculator
  • GST Calculator
  • Gold Loan Calculator
  • EMI Calculator
  • Used Car Loan EMI Calculator
  • Interest Calculator
  • SIP Calculator
  • Credit Score Simulator
  • Flexi Day Wise Interest Calculator
  • Flexi Transaction Calculator
  • Secured Business Loan EMI Calculator
  • Secured Business Loan Eligibility Calculator
  • Lumpsum Calculator
  • Step Up SIP Calculator
  • BMI Calculator
  • IDV Calculator
  • Commercial Loan EMI Calculator
  • Medical Equipment Finance EMI Calculator
  • Term Loan Calculator
  • Equipment Machinery Loan EMI Calculator
  • Doctor Loan EMI Calculator
  • Doctor Loan Eligibility Calculator
  • Chartered Accountant Loan EMI Calculator
  • Simple Interest Calculator
  • Compound Interest Calculator
  • Brokerage Calculator
  • Mutual Fund Calculator
  • Two wheeler Loan EMI Calculator
  • New Car Loan EMI Calculator

Legal

  • Moratorium Policy (Covid-19)
  • Moratorium Policy March 2020
  • Information Security Practices
  • Information Security Measures
  • Citizens Charter
  • Privacy Policy
  • Phishing
  • Disclaimer
  • Forms Centre
  • Fees & Charges
  • Fair Practices Code
  • Interest Rate Policy
  • Disclosures
  • Cautionary Notice
  • Whistle Blower Policy
  • Confidential Feedback
  • Resolution Plan 2.0
  • Terms & Conditions
  • Resolution Plan 2.0 FAQs
  • Ombudsman Scheme
  • SMA/NPA Account Classification
  • Terms of Use
  • Sachet
  • Handover of Property Documents
  • Notices
  • Policy on Fees & Charges
  • BFL - Floating Reference Rates

Reach Us

  • Contact us
  • Raise A Request
  • Frequently Asked Questions
  • Make Online Payment
  • Branch Locator
  • Our Partners
  • Galaxy - Partner portal
  • Bajaj Finserv for Business
  • Call Us

Corporate Office

6th Floor Bajaj Finserv Corporate Office, Off Pune-Ahmednagar Road, Viman Nagar, Pune - 411014

Bajaj Finance Limited Regd. Office

Akurdi, Pune - 411035
Ph No.: 020 7157-6403
Email ID: investor.service@bajajfinserv.in

Corporate Identity Number (CIN)

L65910MH1987PLC042961

IRDAI Corporate Agency (Composite) Regn No.

CA0101
(Valid till 31-Mar-2028)

URN - WEB/BFL/23-24/1/V1

Bajaj Finserv Limited Regd. Office

Bajaj Auto Limited Complex Mumbai - Pune Road,
Pune - 411035 MH (IN)
Ph No.: 020 7157-6064
Email ID: investors@bajajfinserv.in

Corporate Identity Number (CIN)

L65923PN2007PLC130075

Our Companies

  • Bajaj Finserv Ltd.
  • Bajaj Finance Ltd.
  • Bajaj Allianz General Insurance
  • Bajaj Allianz Life Insurance
  • Bajaj Markets
  • Bajaj Housing Finance Ltd.
  • Bajaj Broking
  • Bajaj Finserv Health Ltd.
  • Bajaj Finserv Asset Management Ltd.
Company Name
Download App

© Bajaj Finserv 2007-2025. All rights reserved.